Ignite Creation Date:
2025-12-24 @ 3:02 PM
Ignite Modification Date:
2026-01-29 @ 1:43 PM
Study NCT ID:
NCT00095459
Status:
COMPLETED
Last Update Posted:
2019-12-17
First Post:
2004-11-04
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors
Sponsor:
National Cancer Institute (NCI)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2004-11-02
Start Date Type:
None
Primary Completion Date:
2005-11-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2012-07-20
Completion Date Type:
ACTUAL
First Submit Date:
2004-11-04
First Submit QC Date:
None
Study First Post Date:
2004-11-05
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-12-14
Last Update Post Date:
2019-12-17
Last Update Post Date Type:
ACTUAL